The Life & Science Podcast podcast

The Future is 3D Spatial | Malte Kuhnemund | S1 E3

0:00
1:36:32
Spol 15 sekunder tilbage
Spol 15 sekunder frem

In this episode of The Life & Science Podcast, we talk with Malte Kuhnemund about why spatial biology is flat, and whether it should be.

Malte came to Sweden on an Erasmus exchange in Lund and stayed for his PhD in Uppsala. The in situ technology from his lab became CARTANA, which he co-founded and 10x Genomics acquired, and it fed into the Xenium platform. After 10x closed the Stockholm site, he helped start CubaseBio and Haga Bio.

We discuss:

  • What pulled him to Sweden, from family summers to open professors' doors
  • Building CARTANA when spatial RNA imaging was still "science fiction"
  • Why 10x Genomics, and what signing the papers felt like
  • The Stockholm closure: anger first, then hindsight
  • A break with his kids, then starting CubaseBio and Haga Bio
  • Why spatial tools have been flat all along, and how sequencing rebuilds tissue in 3D
  • The experiment showing molecular crowding is no limit for in situ
  • Sacrifice, founder pressure and advice: "Nothing's safe today"

If you are a scientist thinking about turning research into a company, a founder rebuilding after a reorganisation, a researcher curious about spatial biology in 3D, or a PhD or postdoc weighing academia against industry, you'll recognise yourself in this conversation.

 

Chapters

0:00 Meet Malte Kuhnemund
1:51 Erasmus in Lund, then a PhD in Uppsala
5:24 A mobile phone microscope and the road to CARTANA
7:47 Reagent kits and spatial biology taking off
8:33 Owning your IP in the Swedish system
9:52 Founder, coffee maker and team cheerleader
11:15 Early investors and a market that did not exist
14:19 Why 10x Genomics was the right partner
15:17 An acquisition from the start
16:24 Signing the papers and letting go
18:17 What the CARTANA team brought to the Xenium platform
20:01 Starting again
21:15 When 10x closed the Stockholm site
24:25 Why most of the team stayed in Europe
28:26 Time with his kids and a fresh perspective
31:45 Founding CubaseBio and Haga Bio in 2024
32:18 Two companies with opposite aims
34:45 Haga Bio: taking spatial biomarkers to the clinic
36:40 Why spatial biology has been flat
39:14 "We should have done this in three dimensions"
41:12 Sequencing DNA to see tissue in 3D
42:46 "A billion piece jigsaw puzzle"
45:17 Cells, proteins and the latest preprint
46:29 Computing 3D samples on a workstation
47:22 Organoids and personalised medicine
53:26 Whole transcriptome versus targeted 3D readouts
58:09 Proteins, chromatin and the sequencing cost limit
59:01 Adding time: is 4D next?
1:01:33 Milestones for CubaseBio and Haga Bio
1:04:58 Spatial RNA pathology and a first diagnostic
1:06:50 What changed his mind about in situ
1:13:21 "We're still at the start of spatial biology"
1:22:43 Dutch Courage: sacrifice, balance and delegation
1:25:19 Carrying the pressure of a founder
1:27:02 Being wrong about an R&D decision
1:29:51 Regrets and fears: AI and tool funding
1:32:44 Advice for PhDs, postdocs and founders
1:36:11 "You will find people that can help you" 

Where should spatial biology go next: low-cost assays for the clinic, full 3D for discovery, or both?

Tell us in the comments, and follow The Life & Science Podcast for the next episode. 

#SpatialBiology #SpatialTranscriptomics #BiotechFounders #Organoids #LifeSciences #SRC-Search

https://src-search.com/

Flere episoder fra "The Life & Science Podcast"